IRT-103 + naltrexone

**IRT-103 + naltrexone** is a low-dose naltrexone (LDN) formulation containing 4.5 mg naltrexone hydrochloride, developed as an **active immunotherapy drug** by Immune Therapeutics (now associated with Statera BioPharma). It acts primarily as an **opioid receptor antagonist**, with proposed immunomodulatory effects potentially involving opioid receptor modulation to enhance immune responses and inhibit virus replication. Primarily investigated for **immunosuppressed conditions** such as Crohn's disease and ulcerative colitis (with orphan drug status), it has also been explored for COVID-19 and other inflammatory or infectious diseases. The combination leverages LDN's established off-label use in autoimmune and chronic pain settings, distinguishing it from standard-dose naltrexone used in alcohol/opioid dependence.[2][11][14][17]

Brand names

LODONAL

Other names

Low Dose NaltrexoneLDN